The Third Xiangya Hospital Of Central South University
Clinical trials sponsored by The Third Xiangya Hospital Of Central South University, explained in plain language.
-
New drug combo shows promise in advanced lung cancer trial
Disease control Not yet recruitingThis study tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before radiation therapy can better control stage III lung cancer. About 152 adults will be randomly assigned to receive either the new combination or standard treatment. Researchers …
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New vaccine combo targets Hard-to-Treat pancreatic cancer
Disease control Not yet recruitingThis early-phase study tests a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goals are to check safety and …
Phase: EARLY_PHASE1 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
Smart glucose monitors vs. finger sticks: which works better for diabetes?
Disease control Not yet recruitingThis study looks at 120 adults with type 2 diabetes to see if using a continuous glucose monitor (CGM) helps control blood sugar better than traditional finger-stick testing, when both groups take the drug dapagliflozin. Participants will manage most of the study from home using …
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Tailored blood pressure pills may beat One-Size-Fits-All approach
Disease control Not yet recruitingThis study tests whether choosing blood pressure drugs based on a person's specific heart function (called hemodynamic phenotyping) leads to better blood pressure control than the usual guideline-based method. About 240 adults with mild to moderate hypertension who have never tak…
Phase: PHASE4 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
Can a fungus slow ALS? new trial targets high sphingolipids
Disease control Not yet recruitingThis study tests an oral traditional Chinese medicine made from the fungus C. cicadae in people with ALS who have high levels of certain fats (sphingolipids) in their blood. About 84 participants will receive either the medicine or a placebo for 6 months, with follow-up for 9 mon…
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated May 29, 2026 14:16 UTC